LBLaura Bazzichi

Laura Bazzichi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Laura Bazzichi has a total of 176 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Mo1967 - An Adapted Low Fodmap Diet is Safe and Effective also in the Long Term

    by Massimo Bellini, Alessandra Rossi, Dario Gambaccini, Bernardo Fani, A Ricciardi, Francesco Costa, Angelo Ricchiuti, Gloria M. Mumolo, Laura Bazzichi, Linda Ceccarelli, et al.

  • Low Fodmaps Diet is Safe and Effective, but Patients' Perception is not Always the Reality!

    by Massimo Bellini, Alessandra Rossi, Dario Gambaccini, Silvia Tonelli, Laura Bazzichi, Bernardo Fani, Angelo Ricchiuti, Francesco Costa, Nicola de Bortoli, Gloria M. Mumolo, et al.

    • 27 April 2016
      • Vol. 34, S140-4

    Transdiagnostic factors across fibromyalgia and mental disorders: sleep disturbances may play a key role. A clinical review.

    by Laura Palagini, Claudia Carmassi, Ciro Conversano, Camilla Gesi, Laura Bazzichi, Camillo Giacomelli, Liliana Dell'osso

    Sleep disturbances, affective disorders, pain and fatigue are often present in individuals affected by fibromyalgia (FM). The pathophysiology of FM is not yet well understood and, to date, no treatment has been proven to be fully effective in alleviating all symptoms. Adopting a transdiagnostic perspective could thus be useful for clinicians: treatment would target a transdiagnostic process across a range of disturbances, not just a single disorder. The aim of this review is to revise the available literature about the potential role of sleep disturbances as a transdiagnostic process in FM symptomatology and mood or anxiety disorders comorbidity. We are proposing a model under which sleep disturbances can play a central role. Because conditions of sleep loss are related to the activation of the stress system, including the activation of the inflammation system, we propose this mechanism as a key one: it can be shared by mental, sleep disturbances and pain in FM and it may explain, in part, the high levels of comorbidity between them. In this frame-work sleep disturbances may play a key role and be the target of therapeutic strategies across FM symptomatology and mental disorders.


  • 982 A Low FODMAP Diet in Irritable Bowel Syndrome Improves Symptoms Without Affecting Body Composition and Extracellular Body Water

    by Massimo Bellini, Dario Gambaccini, Lorenzo Bertani, Alessandra Rossi, Angelo Ricchiuti, Maria T. Urbano, Laura Bazzichi, Marta Mosca, Francesco Costa, Gloria M. Mumolo, et al.


    • 18 March 2015
      • Vol. 33, S102-8

    Algo-dysfunctional syndromes: a critical digest of the recent literature.

    by Rossella Talotta, Fabiola Atzeni, Laura Bazzichi, Camillo Giacomelli, Manuela Di Franco, Fausto Salaffi, Piercarlo Sarzi-Puttini

    The etiopathogenesis of the algo-dysfunctional syndromes, which include chronic fatigue syndrome, fibromyalgia and irritable bowel syndrome, is still debated, but it is widely accepted that it is best described by a multifactorial model that include genes, environmental factors such as external infections, inflammation, dietary habits, impaired endogenous cortisol production, the aberrant activation of some areas of the central nervous system, and small peripheral nervous fibre damage. This complexity suggests that they should be managed by means of a multidisciplinary approach involving the use of both pharmacological and non-pharmacological treatments. The aim of this review is to discuss the most recent scientific acquisitions concerning these syndromes and their treatment.


    • 18 March 2015
      • Vol. 33, S109-16

    The inflammatory hypothesis of mood spectrum broadened to fibromyalgia and chronic fatigue syndrome.

    by Liliana Dell'Osso, Laura Bazzichi, Stefano Baroni, Valentina Falaschi, Ciro Conversano, Claudia Carmassi, Donatella Marazziti

    The present paper aimed at reviewing literature data on the inflammatory hypothesis of mood spectrum, as well as the overlapping features with some chronic rheumatologic disorders, in particular fibromyalgia and chronic fatigue syndrome. A literature search was carried out for English papers published in the years 2000-2014, while using the following words: mood spectrum, depression, bipolar disorders, fibromyalgia, chronic fatigue syndrome, neurotransmitters, inflammation, neuroinflammation, cytokines. Overlapping features were highlighted between mood spectrum, fibromyalgia and chronic fatigue syndrome suggesting common underlying mechanisms at pathophysiological level involving both central nervous and the immune systems. Taken together, the literature would suggest that the borders between different medical domains should be reconsidered in the light of common processes linking them.


    • 18 March 2015
      • Vol. 33, S117-25

    Fibromyalgia and nutrition: what news?

    by Alessandra Rossi, Anna Chiara Di Lollo, Maria Paola Guzzo, Camillo Giacomelli, Fabiola Atzeni, Laura Bazzichi, Manuela Di Franco

    Fibromyalgia syndrome (FM) is a chronic, generalised pain condition usually accompanied by several associated symptoms, such as fatigue, sleep disturbance, headache, irritable bowel syndrome and mood disorders. Different medical treatments are used to treat fibromyalgia and the recent guidelines suggest that the optimal treatment consists in a multidisciplinary approach with a combination of pharmacological and non-pharmacological treatment modalities. Among non-pharmacological treatment, nutrition is a promising tool for FM patients. The aim of this review is to update the present knowledge about fibromyalgia and nutrition by means of a systematic search performed on Medline from January 2000 to December 2014. Nutritional deficiencies have been described in FM patients and the benefits of specific diet and nutritional supplementation are shown. Obesity and overweight, often present in FM patients, are related to the severity of FM worsening the quality of life in terms of higher pain, fatigue, worsened sleep quality and higher incidence of mood disorders. Weight control is thus an effective tool to improve the symptoms. Moreover, it seems reasonable to eliminate some foods from the diet of FM patients, for example excitotoxins. Non-coeliac gluten sensitivity is increasingly recognised as a frequent condition with similar manifestations which overlap with those of FM. The elimination of gluten from the diet of FM patients is recently becoming a potential dietary intervention for clinical improvement. In summary, this review reveals the potential benefit of specific dietary interventions as non-pharmacological tools as part of a multidisciplinary treatment for FM patients.


  • Open Access

    Biomarkers in fibromyalgia: a review

    by Camillo Giacomelli, Francesca Sernissi, Alessandra Rossi, Stefano Bombardieri, Laura Bazzichi

    Biomarkers in fibromyalgia: a review Camillo Giacomelli,* Francesca Sernissi,* Alessandra Rossi, Stefano Bombardieri, Laura BazzichiRheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy *These authors contributed equally to the manuscript Fibromyalgia is a common syndrome diagnosed by clinical criteria. The main symptom of fibromyalgia is pain, but patients frequently also complain about other nonspecific symptoms, such as headache, sleep disturbance, mood disorder, and cognitive impairment. In the light of the multifactorial origin of the disease and of the lack of objective diagnostic findings, several attempts have been made to find a reliable biomarker. For this reason, over the years, a number of patients and various biological samples have been studied, using many different approaches and techniques. Despite this, none of these studies has been able to find the proper biomarker. The aim of this review is to provide a critical overview of the current environment characterizing the search for fibromyalgia biomarkers. Keywords: genetics, proteomics, oxidative stress, fibromyalgia


    • 18 December 2013
      • Vol. 31, S153-7

    Fibromyalgia: a critical digest of the recent literature.

    by Camillo Giacomelli, Francesca Sernissi, Piercarlo Sarzi-Puttini, Manuela Di Franco, Fabiola Atzeni, Laura Bazzichi

    Fibromyalgia (FM) syndrome is a chronic disease with unknown etiology, characterised by widespread pain and fatigue. Moreover, several patients manifest non-specific symptoms such as sleep disturbances, mood disorders, and neurocognitive impairment. We have reviewed the literature of the past year to underline the progress of research in the fields of etiopathogenesis, therapies and assessment, considering articles published between November 2012 and November 2013.


    • 26 August 2013
      • Vol. 31  (6) , 857-63

    Drug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and seronegative spondyloarthritis: analysis from the MonitorNet database.

    by Carlo A Scirè, Roberto Caporali, Piercarlo Sarzi-Puttini, Bruno Frediani, Manuela Di Franco, Angela Tincani, Luigi Sinigaglia, Paolo Sfriso, Rosella Tirri, Emanuela Bellis, et al.

    To compare drug survival of different anti-TNF drugs (infliximab, INF, etanercept, ETA, and adalimumab, ADA) in rheumatoid arthritis (RA) and spondyloarthritis (SpA) by analysing data collected from an Italian multicenter observational cohort study. All patients with RA or SpA registered in the MonitorNet database who started their first course of anti-TNF therapy were included. Overall drug survival was measured, along with specific reasons of discontinuation (inefficacy or adverse events). A first set of analyses using RA as reference category assessed the relationship between diagnosis and drug survival. A second set of analyses stratified by diagnosis (RA and SpA) used INF as reference drug. Adjustment for confounders was performed. The results are presented as adjusted hazard ratios (adjHR) and 95% confidence intervals (95%CI). 2640 RA patients and 1220 SpA patients with a median follow-up of 17 months (IQR 7.2-33.4) were included in the analyses. Patients with a diagnosis of SpA showed a lower risk of drug discontinuation with an adjHR (95%CI) of 0.81 (0.73, 0.90). In SpA, the subset of patients with ankylosing spondylitis (AS) showed the best survival on treatment. In RA, both ETA and ADA showed a significantly lower probability of withdrawal when compared to INF [adjHR (95%CI) 0.46 (0.38, 0.56) and 0.68 (0.57, 0.81), respectively]. Similar results were found in SpA. Drug survival for SpA is longer than that in RA mainly due to the AS subgroup. In both RA and SpA, ETA and ADA showed a better retention on treatment when compared to INF.